ABSTRACT
BACKGROUND: Hypertension has been known to increase the risk of obstetric complications. Recently, the American College of Cardiology endorsed lower thresholds for hypertension as systolic blood pressure of 130-139 mmHg or diastolic blood pressure 80-89 mmHg. However, there is a paucity of information regarding the impact of pre-pregnancy blood pressure on pregnancy outcomes. We aimed to evaluate the effect of pre-pregnancy blood pressure on maternal and neonatal complications. METHODS: In this nationwide, population based study, pregnant women without history of hypertension and pre-pregnancy blood pressure < 140/90 mmHg were enrolled. The primary outcome of composite morbidity was defined as any of the followings: preeclampsia, placental abruption, stillbirth, preterm birth, or low birth weight. RESULTS: A total of 375,305 pregnant women were included. After adjusting for covariates, the risk of composite morbidity was greater in those with stage I hypertension in comparison with the normotensive group (systolic blood pressure, odds ratio = 1.68, 95% CI: 1.59 - 1.78; diastolic blood pressure, odds ratio = 1.56, 95% CI: 1.42 - 1.72). There was a linear association between pre-pregnancy blood pressure and the primary outcome, with risk maximizing at newly defined stage I hypertension and with risk decreasing at lower blood pressure ranges. CONCLUSIONS: 'The lower, the better' phenomenon was still valid for both maternal and neonatal outcomes. Our results suggest that the recent changes in diagnostic thresholds for hypertension may also apply to pregnant women. Therefore, women with stage I hypertension prior to pregnancy should be carefully observed for adverse outcomes.
Subject(s)
Blood Pressure , Hypertension/pathology , Pregnancy Complications, Cardiovascular/pathology , Pregnancy Complications/epidemiology , Pregnancy Outcome/epidemiology , Cohort Studies , Databases, Factual , Female , Humans , National Health Programs , Pregnancy , Republic of KoreaABSTRACT
This study examined the bioactivity of yeast (Saccharomyces cerevisiae)-fermented aged black garlic (FBG) on obese mice supplied a high-fat diet (HFD) and its in vitro antioxidant activity. Aged black garlic (BG) exhibits potent antioxidative effects and has been subjected to extensive research. In addition, the bioactivity of some natural products is increased by fermentation. In a preliminary test, this study found that the antioxidant activity of FBG is stronger than that of BG. Therefore, it was hypothesized that the bioactivity of BG would be increased by yeast fermentation and would be a good candidate as a nutraceutical product for improving the oxidative defense systems in older patients or patients affected by various oxidative stresses, for example, diabetes and diabetic complications. To test this hypothesis, the bioactivities of FBG in diabetic and obese mice as well as the antioxidant activity in vitro were examined. After 91 days of continuous HFD supply, the mice showed marked obesity, hyperglycemia, hyperlipemia, and liver and kidney damages. Black garlic and all 3 different doses of FBG showed favorable hepatoprotective, nephroprotective, hypolipidemic, and antiobesity effects compared with the HFD control, but no hypoglycemic effects. In particular, more favorable bioactivity against all 4 HFD-induced diabetic complications was detected in the FBG-treated groups compared with the group given equivalent doses of BG. These findings suggest that the bioactivities of BG can be improved by yeast fermentation.
Subject(s)
Antioxidants/therapeutic use , Diabetes Complications/drug therapy , Dietary Fats/adverse effects , Garlic , Obesity/drug therapy , Phytotherapy , Plant Preparations/therapeutic use , Animals , Antioxidants/pharmacology , Diabetes Mellitus/chemically induced , Female , Fermentation , Garlic/microbiology , Hyperglycemia/drug therapy , Hyperlipidemias/drug therapy , Kidney Diseases/drug therapy , Liver Diseases/drug therapy , Mice , Mice, Inbred ICR , Mice, Obese , Obesity/chemically induced , Plant Preparations/pharmacology , Saccharomyces cerevisiaeABSTRACT
Fucoidans have been extensively studied for their various biological activities but the exact role of fucoidans on the inflammatory processes associated with arthritic disease has not been studied. The effect of the treatment of high, medium and low molecular weight fucoidans (HMWF, MMWF and LMWF, respectively) on the progression of collagen-induced arthritis (CIA) was tested. A daily oral administration of HMWF enhanced the severity of arthritis, inflammatory responses in the joint cartilage and the levels of collagen-specific antibodies, while LMWF reduced the severity of arthritis and the levels of Th1-dependent collagen-specific IgG(2a). Further in vitro analyses, using macrophage cell lines, revealed that the HMWF induced the expression of various inflammatory mediators, and enhanced the cellular migration of macrophages. These stimulatory effects of fucoidan decreased in fucoidans with lower molecular weights and LMWF did not exhibit any pro-inflammatory effects. Interestingly, the oral administration of HMWF enhanced the production of IFN-gamma, one of the Th1 cytokines, in collagen-stimulated spleen cells that had been isolated from CIA mice, while LMWF had the opposite effect. These results indicate that HMWF enhances arthritis through enhancing the inflammatory activation of macrophages while LMWF reduces arthritis through the suppression of Th1-mediated Immune reactions.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Arthritis, Experimental/drug therapy , Cartilage/drug effects , Joints/drug effects , Plant Extracts/therapeutic use , Polysaccharides/therapeutic use , Undaria/chemistry , Animals , Anti-Inflammatory Agents/pharmacology , Arthritis, Experimental/immunology , Arthritis, Experimental/metabolism , Cartilage/metabolism , Cartilage/pathology , Cell Movement/drug effects , Collagen Type II , Immunoglobulin G/blood , Inflammation/chemically induced , Inflammation/drug therapy , Inflammation/metabolism , Inflammation Mediators/metabolism , Interferon-gamma/biosynthesis , Joints/metabolism , Joints/pathology , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred DBA , Molecular Weight , Phytotherapy , Plant Extracts/pharmacology , Polysaccharides/chemistry , Polysaccharides/pharmacology , Severity of Illness Index , Spleen/cytology , Spleen/metabolism , Th1 Cells/metabolismABSTRACT
The purpose of this study was to investigate the improvement of allergic dermatitis in chemical allergen-induced mice by Lactobacillus sakei probio 65. L. sakei probio-65 was isolated from kimchi, a traditional Korean fermented food. This strain was resistant to gastric acidity, bile, and several antibiotics and possessed antimicrobial activity against several pathogenic microorganisms. To investigate whether the probiotic activity of L. sakei probio 65 was effective for treating allergic dermatitis, the organism was supplied to mice triggered by allergen (1-chloro-2,4-dinitrobenzene). Mice that received L. sakei probio 65 showed a more rapid recovery compared to control mice, as assessed by visual evaluation of the severity of allergic dermatitis and levels of immunoglobulin (Ig) E and interleukin (IL)-4. L. sakei probio 65 exhibited good probiotic properties in vitro and in mice and was effective in reducing allergen-induced skin inflammation through the regulation of both elevated IgE and IL-4 in sensitized mice.
Subject(s)
Dermatitis, Atopic/therapy , Lactobacillus , Probiotics/therapeutic use , Animals , Dermatitis, Atopic/chemically induced , Dermatitis, Atopic/immunology , Dinitrochlorobenzene , Female , Immunoglobulin E/blood , Interleukin-4/analysis , Lactobacillus/drug effects , Lactobacillus/genetics , Lactobacillus/isolation & purification , Mice , Mice, Inbred Strains , Microbial Sensitivity Tests , Probiotics/isolation & purification , RNA, Ribosomal, 16S , Spleen/immunologyABSTRACT
Wogonin is a plant monoflavonoid which has been reported to inhibit cell growth and/or induce apoptosis in various tumors. Herein, we investigated the in vitro and in vivo anticancer effects and associated mechanisms of wogonin in human breast cancer. Effects of wogonin were examined in estrogen receptor (ER)-positive and -negative human breast cancer cells in culture for proliferation, cell cycle progression, and apoptosis. The in vivo effect of oral wogonin was examined on tumor xenograft growth in athymic nude mice. The molecular changes associated with the biological effects of wogonin were analyzed by immunoblotting. Cell growth was attenuated by wogonin (50-200 microM), independently of its ER status, in a time- and concentration-dependent manner. Apoptosis was enhanced and accompanied by upregulation of PARP and Caspase 3 cleavages as well as proapoptotic Bax protein. Akt activity was suppressed and reduced phosphorylation of its substrates, GSK-3beta and p27, was observed. Suppression of Cyclin D1 expression suggested the downregulation of the Akt-mediated canonical Wnt signaling pathway. ER expression was downregulated in ER-positive cells, while c-ErbB2 expression and its activity were suppressed in ER-negative SK-BR-3 cells. Wogonin feeding to mice showed inhibition of tumor growth of T47D and MDA-MB-231 xenografts by up to 88% without any toxicity after 4 weeks of treatment. As wogonin was effective both in vitro and in vivo, our novel findings open the possibility of wogonin as an effective therapeutic and/or chemopreventive agent against both ER-positive and -negative breast cancers, particularly against the more aggressive and hormonal therapy-resistant ER-negative types.
Subject(s)
Breast Neoplasms/drug therapy , Cell Proliferation/drug effects , Drugs, Chinese Herbal/therapeutic use , Estrogen Receptor alpha/metabolism , Flavanones/therapeutic use , Animals , Apoptosis/drug effects , Breast Neoplasms/chemistry , Breast Neoplasms/genetics , Caspases/drug effects , Caspases/metabolism , Cyclin D1/genetics , Cyclin D1/metabolism , Estrogen Receptor alpha/genetics , Female , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Receptor, ErbB-2/metabolism , Signal Transduction/drug effects , Tumor Cells, Cultured/drug effects , Xenograft Model Antitumor AssaysABSTRACT
We have suggested ultrafine particle coating processes for preparing nanocrystalline particle coated alpha-alumina powders by a carbonate precipitation and thermal-assisted combustion route, which is environmentally friendly. The nanometric ammonium aluminum carbonate hydroxide (AACH) as a precursor for coating of alumina was produced from precipitation reaction of ammonium aluminum sulfate and ammonium hydrogen carbonate. The synthetic crystalline size and morphology were greatly dependent on pH and temperature. By adding ammonium aluminum sulfate solution dispersed the alpha-alumina core particle in the ammonium hydrogen carbonate aqueous solution, nanometric AACH with a size of 5 nm was tightly bonded and uniformly coated on the core powder due to formation of surface complexes by the adsorption of carbonates, hydroxyl and ammonia groups on the surface of aluminum oxide. The synthetic precursor rapidly converted to amorphous- and y-alumina phase without significant change in the morphological features through decomposition of surface complexes and thermal-assisted phase transformation. As a result, the nanocrystalline polymorphic particle coated alpha-alumina core powders with highly uniform distribution were prepared from the route of carbonate precipitation and thermal-assisted combustion.
Subject(s)
Aluminum Oxide/chemistry , Carbonic Acid/chemistry , Crystallization/methods , Nanostructures/chemistry , Nanostructures/ultrastructure , Nanotechnology/methods , Adsorption , Chemical Precipitation , Gases/chemistry , Hot Temperature , Macromolecular Substances/chemistry , Materials Testing , Molecular Conformation , Particle Size , Powders , Surface PropertiesABSTRACT
Antidiabetic effects of a novel microbial biopolymer (PGB)1 excreted from new Enterobacter sp. BL-2 were tested in the db/db mice. The animals were divided into normal control, rosiglitazone (0.005%, wt/wt), low PGB1 (0.1%, wt/wt), and high PGB1 (0.25%, wt/wt) groups. After 5 weeks, the blood glucose levels of high PGB1 and rosiglitazone supplemented groups were significantly lower than those of the control group. In hepatic glucose metabolic enzyme activities, the glucokinase activities of PGB1 supplemented groups were significantly higher than the control group, whereas the PEPCK activities were significantly lower. The plasma insulin and hepatic glycogen levels of the low and high PGB1 supplemented groups were significantly higher compared with the control group. Specifically, the insulin and glycogen increases were dose-responsive to PGB1 supplement. PGB1 supplement did not affect the IPGTT and IPITT compared with the control group; however, rosiglitazone significantly improved IPITT. High PGB1 and rosiglitazone supplementation preserved the appearance of islets and insulin-positive cells in immunohistochemical photographs of the pancreas compared with the control group. These results demonstrated that high PGB1 (0.25% in the diet) supplementation seemingly contributes to preventing the onset and progression of type 2 diabetes by stimulating insulin secretion and enhancing the hepatic glucose metabolic enzyme activities.